Foundation Medicine was awarded its second consecutive, five-year contract by the U.S. Department of Veterans Affairs
Foundation Medicine, Inc. today announced it was awarded its second consecutive, five-year contract by the U.S. Department of Veterans Affairs (VA) to provide tumor molecular profiling tests and services to eligible Veterans living with cancer as part of the VA’s National Precision Oncology Program. The national contract covers Foundation Medicine’s tissue-based test FoundationOne®CDx, liquid-based test FoundationOne®Liquid CDx, tissue-based RNA sequencing test FoundationOne®RNA and FoundationOne®Heme for hematologic malignancies.
Foundation Medicine’s high-quality diagnostic tests being provided to the VA accurately identify the genomic mutations driving a patient’s cancer and match a patient to the most effective treatment options, including targeted therapies, immunotherapies or clinical trials.
“We are honored to continue our relationship with the VA’s National Precision Oncology Program to provide Veterans with high-quality diagnostic testing,” said Annie Murphy, chief commercial officer at Foundation Medicine. “We know that delivering the right answers requires the confidence that tests reliably produce accurate results. Our comprehensive portfolio of tissue and blood-based tests can simplify complex decisions by generating quality information to enable better decision-making, patient outcomes and treatment options.”
Foundation Medicine was awarded its first contract by the VA in 2019 to provide FoundationOne CDx and FoundationOne®Liquid for solid tumors as well as FoundationOne Heme for hematologic malignancies.
Source – BusinessWire